TỈ LỆ THIẾU MÁU TRÊN BỆNH NHÂN BỆNH THẬN MẠN ĐANG LỌC MÁU CHU KỲ CÓ ĐIỀU TRỊ ERYTHROPOIETIN VÀ MỘT SỐ YẾU TỐ LIÊN QUAN TẠI BỆNH VIỆN NHÂN DÂN GIA ĐỊNH, NĂM 2022

Abstract

Background: Anemia in chronic kidney disease is always a common issue in those who routinely have hemodialysis even after the widely use of Erythropoietin in treatment regimens. Therefore, our study’s objectives are to estimate the anemia rate, the rate of Erythropoietin hyporesponsiveness, and possibly associated factors, including the phosphorus level, nutrition status, iron status and inflammation condition of patients with hemodialysis. Methods: During the months from September to December 2020, a cohort study was conducted using simple random sampling in Nhan Dan Gia Dinh hospital. All incident Erythropoietin users were characterized at baseline and the difference between the baseline hemoglobin (Hb) value, that is the Hb value after 30 days use of Erythropoietin and the outcome Hb value were calculated and defined as delta Hb (ΔHb). Incident ESA users were defined as hyporesponsive if ΔHb < 0 g/dL. Results: In 95 patients in the study, 100% has anemia, based on the definition of WHO, >50% with moderate or severe anemia. Erythropoietin hyporesponsiveness rate is 36.8%. Our study finds out 4 variables associated with the hyporesponsiveness are phosphorus (p=0.042), iron serum (p=0.023), CRP (p=0.007) and Albumin (p=0.041). Conclusions: Our study confirmed the traditional factors associated with Erythropoietin hyporesponsiveness. Once again, it is asserted that periodical laboratory tests are critical not only in the early findings of anemia or Erythropoieitin hyporesponsiveness, but also in supplement therapy in order to improve the ultimate end point of anemia therapy in patients with hemodialysis.